YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimil...
Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism vi...
Biocom California, the association representing the California life science industry, and KoreaBIO, a life science trade association which seeks to solid...
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectu...
LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. y announced an exclusive license and commercialization agreement for Lotus to commercial...
Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...
Amorepacific revealed research findings confirming the skin-regenerative effects of polydeoxyribonucleotides (PDRNs) extracted from a microalgal source,&nb...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly develop...
ABL Bio Inc. a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a wor...
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso...
-SK pharmteco, a global pharmaceutical subcontract development and manufacturing organization, CDMO), has just reached an important step in its sustainab...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
© 2025 Biopharma Boardroom. All Rights Reserved.
